DRAFT qualification opinion for GFR slope as a Surrogate Endpoint in RCT for CKD
Submitted by Anonymous (not verified) on 6 September 2023 - 10:49
DRAFT qualification opinion for GFR slope as a Surrogate Endpoint in RCT for CKD
CooperSurgical Inc ART Media - Procedural steps and scientific information after initial consultation
Submitted by Anonymous (not verified) on 6 September 2023 - 9:34
CooperSurgical Inc ART Media - Procedural steps and scientific information after initial consultation
Origio - Procedural steps and scientific information after initial consultation
Submitted by Anonymous (not verified) on 6 September 2023 - 9:31
Origio - Procedural steps and scientific information after initial consultation
Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Hypertension, Date of authorisation: 30/10/2009, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 5 September 2023 - 14:53
Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Hypertension, Date of authorisation: 30/10/2009, Revision: 16, Status: Authorised
Frequently asked questions about parallel distribution
Submitted by Anonymous (not verified) on 5 September 2023 - 13:24
Frequently asked questions about parallel distribution
Flurbiprofen : List of nationally authorised medicinal products - PSUSA/00001450/202211
Submitted by Anonymous (not verified) on 5 September 2023 - 11:31
Flurbiprofen : List of nationally authorised medicinal products - PSUSA/00001450/202211
Human medicines European public assessment report (EPAR): Zolsketil pegylated liposomal, doxorubicin, Ovarian Neoplasms;Sarcoma, Kaposi;Multiple Myeloma, Date of authorisation: 31/05/2022, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 5 September 2023 - 11:20
Human medicines European public assessment report (EPAR): Zolsketil pegylated liposomal, doxorubicin, Ovarian Neoplasms;Sarcoma, Kaposi;Multiple Myeloma, Date of authorisation: 31/05/2022, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Celdoxome pegylated liposomal, doxorubicin hydrochloride, Breast Neoplasms;Ovarian Neoplasms;Multiple Myeloma;Sarcoma, Kaposi, Date of authorisation: 15/09/2022, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 5 September 2023 - 11:08
Human medicines European public assessment report (EPAR): Celdoxome pegylated liposomal, doxorubicin hydrochloride, Breast Neoplasms;Ovarian Neoplasms;Multiple Myeloma;Sarcoma, Kaposi, Date of authorisation: 15/09/2022, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Sarcoma, Kaposi;Multiple Myeloma;Ovarian Neoplasms;Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 36, Status: Authorised
Submitted by Anonymous (not verified) on 5 September 2023 - 10:53
Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Sarcoma, Kaposi;Multiple Myeloma;Ovarian Neoplasms;Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 36, Status: Authorised
Checklist for the submission of day +5 translations for a post-opinion linguistic review - veterinary
Submitted by Anonymous (not verified) on 5 September 2023 - 10:20
Checklist for the submission of day +5 translations for a post-opinion linguistic review - veterinary